Why Is Profusa, Inc. (PFSA) Stock Up +195.58% Today?
Key Takeaways
- Shares of Profusa, Inc. were up 195.58% in morning trading Tuesday, last at $13.39, compared with Monday's close of $4.53.
- Primary catalyst: The company's previously announced 1-for-4 reverse stock split took effect on August 18, 2026.
- Secondary drivers: An extremely reduced share count, event-driven speculation, and the company's recent option agreement to acquire diagnostics company G3 Vision Labs.
- Market context: The move is company-specific rather than a broad market or sector repricing.
- What traders are watching next: Profusa's upcoming quarterly report, estimated for August 21, and progress on the G3 Vision Labs option and related financing.
Opening Summary
Profusa, Inc. (PFSA) is a Berkeley, California-based digital health and biosensor company developing tissue-integrated sensors for continuous biochemical monitoring. In morning trading Tuesday, shares of the micro-cap medical technology company were up 195.58%, changing hands at $13.39 as of 10:31 a.m. ET, compared with Monday's closing price of $4.53.
The sharp increase reflects the effectiveness of a 1-for-4 reverse stock split, which mechanically re-prices the stock across a smaller number of shares outstanding. While the quoted price is significantly higher, the move is primarily a corporate-action repricing rather than a proportional increase in the company's market value.
1-for-4 Reverse Stock Split Takes Effect
Profusa, Inc. (PFSA) announced that its previously approved 1-for-4 reverse stock split became effective August 18, 2026. The split consolidates every four shares of common stock into one share, leaving the par value unchanged at $0.0001 per share. Fractional shares are not being issued; cash is provided in lieu.
As a result, the company's outstanding share count is reduced from approximately 2,422,906 shares to approximately 605,726 shares, while authorized shares remain at 601 million. This is the third reverse split for PFSA in 2026, following a 1-for-75 split in February and a 1-for-25 split in July. Because the higher quoted price is spread across fewer shares, the headline percentage move overstates any change in shareholder value.
Speculative, Low-Float Trading Amplifies the Move
The reduction in shares outstanding has created an exceptionally low-float trading environment for PFSA. With fewer shares available for trading, order flow can produce outsized percentage swings, and the stock has been attracting event-driven and speculative interest around the split. Trading volume has been elevated relative to the company's typical activity, consistent with a volatile, corporate-action-driven tape rather than a fundamental repricing.
G3 Vision Labs Option Provides Fundamental Backdrop
Beyond the reverse split, PFSA has been in focus following its July 31 announcement of an option agreement to acquire G3 Vision Labs and its diagnostics subsidiaries. G3 reported estimated 2025 net revenues of approximately $111 million based on unaudited management information. The option is subject to conditions including at least $30 million in financing, debt resolution, and stockholder approval.
The potential acquisition would mark a strategic shift for the biosensor company toward a commercial-stage diagnostics platform with CLIA-certified laboratories. While the G3 agreement is not the immediate trigger for Tuesday's price action, it has contributed to elevated attention on the stock and supports the broader speculative narrative around the company's transformation.
Market Context and Trading Activity
Tuesday's move in PFSA is company-specific. There is no clear sector-wide catalyst or broad market event driving the repricing, and the move is not aligned with a major healthcare or medical-device index trend. The action is consistent with a micro-cap stock undergoing a reverse split, where technical levels and traditional valuation metrics are less relevant than share-count mechanics and liquidity conditions.
What Comes Next for PFSA
Traders are now focused on Profusa's next quarterly report, estimated for August 21 before the market open, which could provide updated financial detail and commentary on the company's strategic direction. Attention also remains on the G3 Vision Labs option, including whether the company can satisfy the financing and approval conditions required to exercise it.
Risks include continued volatility from the reduced share count, uncertainty around the G3 transaction, potential dilution from convertible preferred stock, and the company's history of multiple reverse splits. While the quoted share price has risen sharply, the underlying business and financing milestones remain the key fundamental considerations.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI trading bots that are currently among the strongest performers under prevailing market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by timeframe, trading style, performance metrics, and traded symbols. Traders interested in data-driven tools can review the page to see which AI-driven strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PFSA in +13.61% Uptrend, rising for three consecutive days on September 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where PFSA advanced for three days, in 25 of 57 cases, the price rose further within the following month. The odds of a continued upward trend are 44%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for PFSA just turned positive on September 16, 2026. Looking at past instances where PFSA's MACD turned positive, the stock continued to rise in 8 of 42 cases over the following month. The odds of a continued upward trend are 19%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFSA as a result. In 15 of 51 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 29%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for PFSA entered a downward trend on September 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (10.930). P/E Ratio (0.000) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. PFSA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFSA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices